They have a drug at stage 3 yet destroyed shareholder values.Regardless of how much they talk up this preclinical result No one in the market would be interested. They have unfortunately lost their credibility. It’s going to be a good year for the management? I am confident it would be. Would it be a good year for the shareholders? I am not too sure
Ann: NNZ-2591 positive effects in Phelan-McDermid syndrome model, page-8
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.96 |
Change
-2.150(9.30%) |
Mkt cap ! $2.676B | |||
| Open | High | Low | Value | Volume |
| $22.50 | $22.70 | $20.28 | $24.29M | 1.141M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 259 | $20.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.98 | 1641 | 2 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.07 |
Change
-2.150 ( 9.39 %) |
||||
| Open | High | Low | Volume | ||
| $22.45 | $22.67 | $20.27 | 399615 | ||
| Last updated 15.59pm 29/05/2024 ? | |||||
| NEU (ASX) Chart |